NASDAQ:DRIODarioHealth Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DarioHealth Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.83 -0.08 (-1.16 %) (As of 07/10/2020 10:06 AM ET) Add Compare Share Today's Range$6.83Now: $6.83▼$6.9450-Day Range$5.70MA: $6.41▼$7.0052-Week Range$3.02Now: $6.83▼$13.13Volume1,371 shsAverage Volume79,489 shsMarket Capitalization$25.87 millionP/E RatioN/ADividend YieldN/ABeta0.45 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, DarioHealth has a potential upside of 30.2% from its current price of $6.91.Amount of Analyst CoverageDarioHealth has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesDarioHealth has received 220 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDarioHealth has received 208 “underperform” votes. (Add your “underperform” vote.)Community SentimentDarioHealth has received 51.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DarioHealth and other stocks. Vote “Outperform” if you believe DRIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,050.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 18.30% of the stock of DarioHealth is held by insiders.Percentage Held by InstitutionsOnly 8.41% of the stock of DarioHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRIO Previous Symbol CUSIPN/A CIKN/A Webwww.mydario.com Phone972-4770-4055Debt Debt-to-Equity Ratio0.02 Current Ratio4.37 Quick Ratio4.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.56 million Price / Sales3.42 Cash FlowN/A Price / Cash FlowN/A Book Value$8.45 per share Price / Book0.81Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,740,000.00 Net Margins-318.61% Return on Equity-200.83% Return on Assets-135.82%Miscellaneous Employees69 Outstanding Shares3,790,000Market Cap$25.87 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:DRIO Rates by TradingView Receive DRIO News and Ratings via Email Sign-up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter. DarioHealth (NASDAQ:DRIO) Frequently Asked Questions How has DarioHealth's stock been impacted by COVID-19 (Coronavirus)? DarioHealth's stock was trading at $6.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRIO stock has increased by 0.3% and is now trading at $6.91. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DarioHealth? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DarioHealth. When is DarioHealth's next earnings date? DarioHealth is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for DarioHealth. How were DarioHealth's earnings last quarter? DarioHealth Corp (NASDAQ:DRIO) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($1.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.82. The company had revenue of $1.67 million for the quarter. DarioHealth had a negative net margin of 318.61% and a negative return on equity of 200.83%. View DarioHealth's earnings history. What price target have analysts set for DRIO? 2 analysts have issued twelve-month price targets for DarioHealth's shares. Their forecasts range from $8.00 to $10.00. On average, they expect DarioHealth's share price to reach $9.00 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View analysts' price targets for DarioHealth. Has DarioHealth been receiving favorable news coverage? News coverage about DRIO stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DarioHealth earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about DarioHealth. Are investors shorting DarioHealth? DarioHealth saw a increase in short interest in June. As of June 30th, there was short interest totaling 19,200 shares, an increase of 481.8% from the June 15th total of 3,300 shares. Based on an average daily volume of 68,200 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.7% of the company's stock are sold short. View DarioHealth's Current Options Chain. Who are some of DarioHealth's key competitors? Some companies that are related to DarioHealth include Spectral Medical (EDTXF), Venus Concept (VERO), PAVmed (PAVM), SANUWAVE Health (SNWV), Nephros (NEPH), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPHD), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Neuronetics (STIM) and Apollo Endosurgery (APEN). View all competitors. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include AEterna Zentaris (AEZS), Vascular Biogenics (VBLT), NANO DIMENSION/S (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), AbbVie (ABBV), Dropcar (DCAR), Evoke Pharma (EVOK), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO). Who are DarioHealth's key executives? DarioHealth's management team includes the following people: Mr. Erez Raphael, CEO & Director (Age 46)Mr. Olivier R. Jarry, Pres & Chief Commercial Officer (Age 58)Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 58)Mr. Dror Bacher, Chief Operating Officer (Age 44)Ms. Joao Mendes-Roter, VP of Marketing What is DarioHealth's stock symbol? DarioHealth trades on the NASDAQ under the ticker symbol "DRIO." How do I buy shares of DarioHealth? Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DarioHealth's stock price today? One share of DRIO stock can currently be purchased for approximately $6.91. How big of a company is DarioHealth? DarioHealth has a market capitalization of $26.19 million and generates $7.56 million in revenue each year. DarioHealth employs 69 workers across the globe. What is DarioHealth's official website? The official website for DarioHealth is www.mydario.com. How can I contact DarioHealth? DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
